באייר ישראל בע"מ - תוצאות חיפוש

cts chemical industries ltd, israel - montelukast as sodium - טבליות לעיסות - montelukast as sodium 4 mg - montelukast - montelukast - take air is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. take air is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. take air and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. take air is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

ישראל - עברית - Ministry of Health

מונטאייר 5 מג

cts chemical industries ltd, israel - montelukast as sodium - טבליות לעיסות - montelukast as sodium 5 mg - montelukast - montelukast - take air is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. take air is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. take air and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. take air is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

ישראל - עברית - Ministry of Health

זולאייר 150 מג

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.